Tumour-cell-vaccine-GVAX

Drug Profile

Tumour-cell-vaccine-GVAX

Alternative Names: CG-1940/CG-8711; CG-8123; GVAX Leukemia; GVAX Pancreas; GVAX Prostate; STINGVAX™

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Genesys
  • Developer Aduro BioTech; ANI Pharmaceuticals; BioSante Pharmaceuticals; Cell Genesys; Dana-Farber Cancer Institute; Hussman Foundation; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Cancer vaccines; Gene therapies; Tumour cell vaccines
  • Mechanism of Action Gene transference; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Malignant melanoma; Acute myeloid leukaemia; Chronic myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Pancreatic cancer
  • Phase I/II Prostate cancer
  • No development reported Breast cancer; Cancer; Chronic myeloid leukaemia; Malignant melanoma; Multiple myeloma
  • Discontinued Non-small cell lung cancer; Renal cancer

Most Recent Events

  • 18 Jun 2017 Sidney Kimmel Comprehensive Cancer Center, Bristol-Myers Squibb and Aduro Biotech plan the phase II trial for Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03190265)
  • 26 May 2017 Phase-II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (NCT02981524)
  • 23 May 2017 Sidney Kimmel Comprehensive Cancer Center plans a phase II trial for Pancreatic cancer (Combination therapy, In adults, In the elderly) (NCT03161379)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top